During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.

Medtech Insight spoke with Outset Medical’s CEO Leslie Trigg about lessons learned in her career growing medtechs and her plans for growing Tablo hemodialysis for acute and home care. 

Outset’s at-home dialysis system is the first technology approved for Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES), a designation created for US Medicare kidney patients.

Changes to the mandatory payment model now used by the US Centers for Medicare & Medicaid Services (CMS) for kidney disease would encourage facilities to provide treatment to lower income patients.